Practice Areas
Michael Shuster is a partner in Goodwin’s Life Sciences group, providing strategic intellectual property advice to biotechnology, chemical, pharmaceutical, and other life sciences companies. He handles an array of IP matters – including patent prosecution, portfolio analysis, due diligence, litigation, and opinion work – for clients ranging from startups to established biotechnology companies, venture capital firms, and research universities and hospitals. He also provides IP evaluation and counseling for companies raising and investing growth capital, executing strategic partnerships and M&A transactions, and going public.
Leveraging a background in science, Michael has advised extensively on IP issues related to immunotherapy, antibody technologies, microbiome-based technologies, ag biotechnology, biologics, gene therapy, therapeutic vaccines, synthetic biology, small molecule therapeutics, and drug formulations, among other complex technologies.
Before attending law school, he was part of a Columbia University team, led by Professor Eric Kandel, that conducted research into the mechanisms underlying short-term memory storage. Kandel was awarded the 2000 Nobel Prize in Medicine for a body of work that included that project.
Personal
JD, University of San Francisco School of Law, 1997 (cum laude); PhD, Columbia University, The Department of Physiology and Molecular Biophysics, 1986; BA, Biophysics, Brandeis University, 1981 (magna cum laude)
